Karl Storz intends to boost its presence in the robotic surgical market. Credit: fernando zhiminaicela / Pixabay.

Karl Storz Endoscopy-America, a subsidiary of medical technology company Karl Storz Se & Co, has agreed to acquire Asensus Surgical.

Under the agreement, KARL STORZ will acquire all outstanding shares of Asensus for $0.35 per share in cash.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The purchase price reflects a premium of around 67%, based on the closing price of Asensus’ common stock on 2 April 2024; and a 52% premium over the last trading day before the announcement.

Asensus’ board of directors has unanimously approved the transaction.

The acquisition is expected to bolster Karl Storz’s portfolio and presence in the robotic surgical market, especially with the development of the LUNA system.

See Also:

Subject to standard closing conditions and approval from Asensus shareholders, the merger is anticipated to conclude in the third quarter of 2024.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Following the merger, Asensus will operate as a subsidiary of Karl Storz Endoscopy-America and also be delisted from the NYSE American Exchange.

Asensus Surgical president and CEO Anthony Fernando said: “We are pleased to have reached this agreement with KARL STORZ, which we believe maximises value for our stockholders.

“This transaction is a testament to the value of our innovative robotic and digital technology, intellectual property, and the hard work of our talented team.

“We are excited to enter the next chapter for Asensus with Karl Storz, which will allow us to continue to develop and deliver precise, safer, predictable surgery and digital tools to patients and surgeons around the world.”

Financial advisory services for Asensus were provided by Jefferies, with Ballard Spahr acting as legal counsel.

Karl Storz received financial advice from UBS Investment Bank and legal counsel from Ropes & Gray.

Last year, Asensus secured the CE mark for the expanded machine vision capabilities of its previously cleared Intelligent Surgical Unit.